Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark
A major nationwide Danish cohort study has found no link between maternal acetaminophen use during pregnancy and autism in children. The new evidence on prenatal acetaminophen autism risk should reassure clinicians and expectant mothers, as both population-wide and sibling-controlled analyses sho...
Amyloid-Beta Treatment Impact: Limited Clinical Benefits and Increased Risks in Early Alzheimer’s...
Amyloid-Beta Treatment Impact on people with early Alzheimer’s disease is minimal, according to a major new Cochrane review. The analysis of 17 randomized controlled trials involving more than 20,000 participants found that amyloid-beta-targeting monoclonal antibodies deliver only trivial improve...
HIV Prevention Partnerships: Expanding Access to Lenacapavir for Global Impact
HIV Prevention Partnerships between PEPFAR, The Global Fund, and Gilead Sciences are accelerating access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) in high-burden countries.
Unprecedented Speed to Sub-Saharan Africa
This additional i...